1. Главная
  2. Ресурсы
  3. Библиотечный поиск
Brivaracetamsubstituting otherantiepileptictreatments: Resultsof a retrospectivestudy in Germanepilepsy centers Holger LercheSusanne KnakeFelix Rosenow2020 год

Brivaracetam substituting other antiepileptic treatments: Results of a retrospective study in German epilepsy centers
статья из журнала

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: Abstract Objective To evaluate the success of initiation of adjunctive brivaracetam in patients who required a change in antiepileptic drug (AED) regimen and substituted at least one AED with brivaracetam. Methods In this retrospective noninterventional study conducted in specialized epilepsy centers across Germany, patients initiated adjunctive brivaracetam between February 15, 2016, and August 31, 2016, as part of an intended change in AED regimen. The primary effectiveness variable was the proportion of patients who continued on brivaracetam after 3 months, and withdrew at least one AED either before or within 6 months after brivaracetam initiation. Results Five hundred and six patients had at least one brivaracetam dose and were included in the safety set (SS). Four hundred and seventy patients started to reduce the dose of one AED before/after brivaracetam initiation, had at least one concomitant AED at brivaracetam initiation, and were included in the full analysis set (FAS) for effectiveness analyses. At baseline, patients had a median of seven lifetime AEDs and a median of 3.8 seizures/28 days. In the SS, 85.2% of patients withdrew one AED before/after initiation of brivaracetam, most commonly levetiracetam (49.4%). 46.2% of patients substituted another AED with brivaracetam within 24 hours (fast withdrawal). The proportions of patients (FAS) who continued on brivaracetam after 3 and 6 months and withdrew one AED were 75.5% and 46.6%, respectively. After 6 months, 32.1% of patients were 50% responders; 13.0% were seizure‐free. In the SS, 34.6% of patients reported treatment‐emergent adverse events (TEAEs); 21.9% had TEAEs that were assessed by the treating physician as drug‐related. Incidences of behavioral AEs before (3‐month baseline) and after brivaracetam initiation in patients who withdrew levetiracetam were 19.2% and 8.0%, respectively (5.0% and 7.7% in patients who withdrew other AEDs). Significance Brivaracetam was effective and well‐tolerated in patients who required a change in AED drug regimen and initiated adjunctive brivaracetam in German clinical practice.
Год издания: 2020
Авторы: Holger Lerche, Susanne Knake, Felix Rosenow, Andreas Schulze‐Bonhage, Scarlett Hellot, Iryna Leunikava, Anne‐Liv Schulz, Peter Hopp
Издательство: Wiley
Источник: Epilepsia Open
Ключевые слова: Epilepsy research and treatment, Pharmacological Effects and Toxicity Studies, Antibiotics Pharmacokinetics and Efficacy
Другие ссылки: Epilepsia Open (PDF)
Epilepsia Open (HTML)
DOAJ (DOAJ: Directory of Open Access Journals) (HTML)
Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (PDF)
Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (HTML)
PubMed Central (HTML)
PubMed (HTML)